Since VEGFR-2 plays a significant role in neovascularization after TACE [21], the combination of TACE and apatinib may improve the outcome of the treatment of advanced HCC due to selective inhibition of VEGFR-2. The gene discussed is KDR; the disease is hepatocellular carcinoma.